Glycoprotein News and Research

RSS

New antibody assay for COVID-19 promises sensitive mass-scale detection

A new paper by researchers at McMaster University and Hamilton Health Sciences, published on the preprint server medRxiv in September 2020, reports on the development of a serologic assay that is suitable for sensitive high-throughput antibody testing for COVID-19.

15 Sep 2020

Computational models screen for coronaviruses likely to infect humans

The researchers from Rochester Institute of Technology and the Hauptmann-Woodward Medical Research Institute produced models of the receptor-binding domain (RBD) found on outbreak strains of betacoronaviruses and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2).

14 Sep 2020

A map of SARS-CoV-2 escape mutations enables the development of therapeutic antibody cocktails

A recent tour-de-force study by the US researchers describes a comprehensive approach to completely map mutations to the SARS-CoV-2 receptor-binding domain (RBD) that escape antibody binding – enabling, in turn, rational design of antibody therapeutics and appraisal of the antigenic consequences of viral evolution. The results are currently available in a bioRxiv preprint paper.

13 Sep 2020

New, rapid test detects ovarian cancer more accurately

The CA125 antigen, a plasma membrane glycoprotein found in the tissues of the female reproductive tract, is commonly used for the detection of ovarian cancer but works poorly on its own in identifying early stage cancers.

11 Sep 2020

Detecting SARS-CoV-2 in 30 seconds with cheap and sensitive nanotubes

In a fascinating new medRxiv preprint paper, researchers from the University of Nevada, Reno demonstrate the power of cobalt-functionalized titanium dioxide nanotubes by selectively detecting the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in less than 30 seconds.

10 Sep 2020

Study reveals how B cells react to SARS-CoV-2

In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.

9 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

Early in the pandemic, scientists uncovered the role of the ACE2 receptor in SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the angiotensin-converting enzyme 2 (ACE2) receptors act as a lock and key for cell infection.

7 Sep 2020

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Based on structural similarities with other targets of the gamma-secretase system, researchers from Columbia University Irving Medical Center in the United States show that the SARS-CoV-2 receptor for cell entry may be affected by its proteolytic activity. Their results are currently freely available in a bioRxiv preprint paper.

6 Sep 2020

Spike-based priming leads to high neutralizing activity in animal models

A new report by researchers at the University of Melbourne and published on the preprint server bioRxiv in September 2020 reports on the use of a two-protein two-dose vaccine regimen and its immunogenicity in two animal models.

4 Sep 2020

UC San Diego participates in second, massive clinical trial of COVID-19 vaccine

UC San Diego Health will be part of a second, massive clinical trial to assess the safety, efficacy and immunogenicity of a vaccine designed to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19.

2 Sep 2020

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Now, a new study published on the preprint server bioRxiv* in August 2020 reports the induction of neutralizing antibodies in mice by a single dose of a ferritin nanoparticle-based vaccine containing the spike protein.

1 Sep 2020

Using SARS-CoV-2 epitope to construct a vaccine

A new study published on the preprint server bioRxiv* in August 2020 reports the use of prediction and advanced simulation techniques to identify a novel T cell epitope on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as the basis for a customized vaccine with broad-based efficacy.

30 Aug 2020

SARS-CoV-2 Neucleocapside (N) protein is heavily glycosylated

However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint server bioRxiv in August 2020 reveals the structure of this protein, a valuable step in using it for these purposes.

30 Aug 2020

Study shows furin cleavage site is crucial for SARS-CoV-2 replication

In a recent bioRxiv* preprint paper, researchers from the United States demonstrate the pivotal role the furin cleavage site insertion in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein plays in viral replication and pathogenesis – highlighting, in turn, the need for mutation monitoring when developing therapeutics and vaccines.

27 Aug 2020

Ferrets not susceptible to SARS-CoV-2 infection

A recent study by scientists at the Cummings School of Veterinary Medicine at Tufts University has revealed that ferrets are not susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection even if they are directly exposed to symptomatic coronavirus disease 2019 (COVID-19) patients for a prolonged time.

24 Aug 2020

New SARS-CoV-2 vaccine effective in macaques

Researchers from the biotechnology company Novavax in Gaithersburg, Maryland, have developed a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that successfully induces immunogenicity and protection against the virus in macaques.

20 Aug 2020

COVID-19 could compromise key element of immune response

Researchers at the University of Melbourne have made the unsettling discovery that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might compromise the activation of the CD8+ T-cell responses that would usually ameliorate disease and drive recovery in cases of respiratory disease.

20 Aug 2020

Researchers develop vaccine for human herpesvirus 6B

A research group led by Professor MORI Yasuko (of the Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine) has revealed that the HHV-6B glycoprotein complex gH/gL/gQ1/gQ2 is an effective vaccine candidate for human herpesvirus 6B (HHV-6B).

20 Aug 2020

Could the high rate of mutations bring about SARS-CoV-2's extinction in India?

A new study published on the preprint server bioRxiv in August 2020 shows the importance of uncovering the dynamics of the virus with particular attention to geographic variation.

19 Aug 2020